Filing Flows › Ocular Therapeutix (OCUL) › Recalls, complaints & regulation
Ocular Therapeutix (OCUL): clinical trials
Ocular Therapeutix (OCUL) beyond its filings: 4 active clinical trials.
Ocular Therapeutix's latest quarter
Ocular Therapeutix, Q2 2026: revenue $13.5M (+0.1% year over year), operating margin -609.3%, net loss $78.8M, operating cash flow −$67.3M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Ocular Therapeutix have?
4 active studies on ClinicalTrials.gov, 4 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.